Novartis Aktie
128,14
EUR
-0,16
EUR
-0,12
%
128,16
EUR
-0,82
EUR
-0,64
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Novartis Aktie Analyse
| 21.07.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 21.07.21 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 21.07.21 | Novartis Buy | UBS AG | |
| 21.07.21 | Novartis Buy | Jefferies & Company Inc. | |
| 20.07.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 12.07.21 | Novartis Buy | Jefferies & Company Inc. | |
| 06.07.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 24.06.21 | Novartis Hold | Kepler Cheuvreux | |
|
Werbung
|
|||
| 17.06.21 | Novartis buy | Deutsche Bank AG | |
| 15.06.21 | Novartis buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 07.06.21 | Novartis Neutral | Credit Suisse Group | |
| 04.06.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 04.06.21 | Novartis buy | UBS AG | |
| 04.06.21 | Novartis buy | Jefferies & Company Inc. | |
| 21.05.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 19.05.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 19.05.21 | Novartis buy | Deutsche Bank AG | |
| 14.05.21 | Novartis buy | UBS AG | |
| 11.05.21 | Novartis buy | Deutsche Bank AG | |
| 10.05.21 | Novartis buy | UBS AG | |
| 30.04.21 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 30.04.21 | Novartis buy | Deutsche Bank AG | |
| 28.04.21 | Novartis Underweight | Barclays Capital | |
| 28.04.21 | Novartis Neutral | Credit Suisse Group | |
| 28.04.21 | Novartis buy | Deutsche Bank AG | |
| 28.04.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 27.04.21 | Novartis buy | Jefferies & Company Inc. | |
| 27.04.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 27.04.21 | Novartis Underweight | Barclays Capital | |
| 27.04.21 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 27.04.21 | Novartis buy | UBS AG | |
| 27.04.21 | Novartis market-perform | Bernstein Research | |
| 22.04.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 09.04.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 07.04.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 23.03.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 23.03.21 | Novartis buy | Jefferies & Company Inc. | |
| 23.03.21 | Novartis market-perform | Bernstein Research | |
| 23.03.21 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 22.03.21 | Novartis market-perform | Bernstein Research | |
| 10.03.21 | Novartis buy | Deutsche Bank AG | |
| 09.03.21 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 09.03.21 | Novartis buy | Jefferies & Company Inc. | |
| 18.02.21 | Novartis buy | UBS AG | |
| 18.02.21 | Novartis buy | Deutsche Bank AG | |
| 16.02.21 | Novartis buy | Deutsche Bank AG | |
| 10.02.21 | Novartis buy | Deutsche Bank AG | |
| 09.02.21 | Novartis buy | Deutsche Bank AG | |
| 03.02.21 | Novartis buy | UBS AG | |
| 03.02.21 | Novartis Underweight | JP Morgan Chase & Co. | |
Werbung
Werbung